Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens.

Lim E, Browning J, MacGregor D, Davis ID, Cebon JS.

Melanoma Res. 2006 Aug;16(4):347-55.

PMID:
16845331
2.

Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy.

Trefzer U, Hofmann M, Reinke S, Guo YJ, Audring H, Spagnoli G, Sterry W.

Melanoma Res. 2006 Apr;16(2):137-45.

PMID:
16567969
3.

Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma.

Errington JA, Conway RM, Walsh-Conway N, Browning J, Freyer C, Cebon J, Madigan MC.

Br J Ophthalmol. 2012 Mar;96(3):451-8. doi: 10.1136/bjophthalmol-2011-300432. Epub 2011 Dec 20.

PMID:
22190731
4.
5.

Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.

de Vries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, van Muijen GN.

Cancer Res. 1997 Aug 1;57(15):3223-9.

7.

Expression of melanoma-associated antigens in melanoma cell cultures.

Urosevic M, Braun B, Willers J, Burg G, Dummer R.

Exp Dermatol. 2005 Jul;14(7):491-7.

PMID:
15946236
8.

The new melanoma markers: MART-1 and Melan-A (the NIH experience)

Fetsch PA, Marincola FM, Abati A.

Am J Surg Pathol. 1999 May;23(5):607-10. No abstract available.

PMID:
10328095
9.

Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.

Cormier JN, Abati A, Fetsch P, Hijazi YM, Rosenberg SA, Marincola FM, Topalian SL.

J Immunother. 1998 Jan;21(1):27-31.

PMID:
9456433
10.

Tumor antigen expression in melanoma varies according to antigen and stage.

Barrow C, Browning J, MacGregor D, Davis ID, Sturrock S, Jungbluth AA, Cebon J.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):764-71.

11.

Quantitative assessment of the expression of melanoma-associated antigens by non-competitive reverse transcription polymerase chain reaction.

Ringhoffer M, Schmitt M, Karbach J, Jäger E, Oesch F, Arand M.

Int J Oncol. 2001 Nov;19(5):983-9.

PMID:
11604998
12.

High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma.

Hofbauer GF, Burkhart A, Schüler G, Dummer R, Burg G, Nestle FO.

J Immunother. 2004 Jan-Feb;27(1):73-8.

PMID:
14676635
13.

Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.

Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F, Cascinelli N, Parmiani G, Anichini A.

Cancer Res. 2003 May 15;63(10):2535-45.

14.

High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma.

de Vries TJ, Trancikova D, Ruiter DJ, van Muijen GN.

Br J Cancer. 1998 Nov;78(9):1156-61.

15.

Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas.

Xu X, Chu AY, Pasha TL, Elder DE, Zhang PJ.

Am J Surg Pathol. 2002 Jan;26(1):82-7.

PMID:
11756773
17.

Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.

Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A, Weidmann E, Altmannsberger HM, Knuth A, Jäger E.

Cancer Res. 2005 May 1;65(9):3937-41.

18.

Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.

Benlalam H, Linard B, Guilloux Y, Moreau-Aubry A, Derré L, Diez E, Dreno B, Jotereau F, Labarrière N.

J Immunol. 2003 Dec 1;171(11):6283-9.

19.

Expression of MAGE, gp100 and tyrosinase genes in uveal melanoma cell lines.

Luyten GP, van der Spek CW, Brand I, Sintnicolaas K, de Waard-Siebinga I, Jager MJ, de Jong PT, Schrier PI, Luider TM.

Melanoma Res. 1998 Feb;8(1):11-6.

PMID:
9508371
20.

Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.

Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA.

J Immunother Emphasis Tumor Immunol. 1996 May;19(3):192-205.

PMID:
8811494

Supplemental Content

Support Center